Sign in

CIK 0001714899 · Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
463872213
Phone
(650) 866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Open-market sale Chief Medical Officer sold 1,654 shares at $22.29 ($36,868)
  2. 4 Planned sale Director sold 11,439 shares at an average $22.90 ($261,929)
  3. 4 Planned sale COFO and Secretary sold 2,768 shares at $23.44 ($64,882)
  4. 4 Gift President and CEO gave 32,220 shares (gift)
  5. 4 Open-market sale COFO and Secretary sold 2,857 shares at $25.07 ($71,625)
  6. 4 Grant or award Director acquired 6,408 shares (grant or award)
  7. 4 Grant or award Director acquired 6,408 shares (grant or award)
  8. 4 Grant or award Director acquired 6,408 shares (grant or award)
  9. 4 Grant or award Director acquired 6,408 shares (grant or award)
  10. 4 Grant or award Director acquired 6,408 shares (grant or award)
  11. 4 Grant or award Director acquired 6,408 shares (grant or award)
  12. 4 Grant or award Director acquired 6,408 shares (grant or award)
  13. 4 Grant or award Director acquired 12,816 shares (grant or award)
  14. 3/A Insider 3/A
  15. 3 Insider Initial Statement of Ownership
  16. 4 Open-market sale President and CEO sold 35,198 shares at $16.50 ($580,767)
  17. 4 Open-market sale COFO and Secretary sold 17,218 shares at $16.50 ($284,097)
  18. 4 Grant or award COFO and Secretary acquired 57,700 shares (grant or award)
  19. 4 Grant or award President and CEO acquired 78,960 shares (grant or award)
  20. 4 Derivatives Options or other derivatives

Page 1 of 22 · 436 filings